This drug will be tested in 3.800 men in Europe and America, in a course of 24 to 36 months. The results will be published in 2023.
A prototype HIV vaccine reached the third phase of clinical trials for the first time in 10 years. The protection and permanence of this drug will have to be measured for 24 to 36 months.
HIV is a virus that, if not treated in time, can cause AIDS. However, the latest advances in science and medicine have helped make this disease not fatal, but rather a chronic condition controlled by lifelong treatments.
The vaccine is developed by the Belgian-American pharmaceutical company Janssen, who used an adenovirus modified with HIV proteins, so that the body creates antibodies against the different strains of the virus.
The main problems in building a vaccine against HIV are the high variations that the virus has; however, the drug developed by Janssen contains mosaic immunogens, which can elicit an immune response against various strains.
On the other hand, the vaccine will be tested in 3.800 men between the ages of 18 and 60 in Europe and America. Each volunteer will receive the vaccine or the placebo of the same in a course of 24 to 36 months, the final results will be published in 2023.
Source: El País – BBC
Be the first to comment